News
November 07, 2025
Lumonus Raises A$25 Million in Series B to Scale AI Powered Oncology Workflows Globally
SYDNEY, Nov. 6, 2025 /PRNewswire/ -- Lumonus, a leader in AI powered radiation oncology workflow solutions, today announced the close of its A$25 million Series B financing round. The round was led by Aviron Investment Management with continued participation from...
Sydney, Australia – November 6, 2025 – Lumonus, an Australian company revolutionizing cancer treatment through artificial intelligence, has secured A$25 million in Series B funding. This significant investment will fuel the company's ambition to expand its AI-powered radiation oncology workflow solutions on a global scale.
The funding round was spearheaded by Aviron Investment Management, demonstrating strong confidence in Lumonus's technology and its potential to transform cancer care. Existing investors also continued their support, highlighting the company's consistent progress and promising future.
Lumonus specializes in developing AI solutions that streamline and optimize the complex processes involved in radiation oncology. Radiation oncology, a critical component of cancer treatment, involves carefully targeting cancerous tumors with high-energy radiation beams. This requires meticulous planning, precise execution, and continuous monitoring to ensure effective treatment while minimizing damage to healthy tissues.
Lumonus's AI platform assists clinicians at every stage of this process, from initial planning and simulation to treatment delivery and post-treatment analysis. By automating repetitive tasks, improving accuracy, and providing data-driven insights, Lumonus aims to reduce treatment times, enhance patient outcomes, and alleviate the burden on healthcare professionals.
The A$25 million investment will enable Lumonus to accelerate its research and development efforts, expand its team of experts, and broaden its reach to new markets around the world. This expansion will allow more cancer centers and patients to benefit from the company's innovative AI solutions, ultimately contributing to improved cancer treatment globally.
"This Series B funding is a significant milestone for Lumonus," said a company spokesperson. "It validates our vision of using AI to transform radiation oncology and improve the lives of cancer patients. We are excited to partner with Aviron Investment Management and our existing investors to bring our solutions to a wider audience and make a meaningful impact on the fight against cancer."
The investment in Lumonus underscores the growing importance of artificial intelligence in healthcare and its potential to revolutionize various aspects of medical practice. As the demand for personalized and efficient cancer treatment continues to rise, companies like Lumonus are poised to play a crucial role in shaping the future of oncology.
The funding round was spearheaded by Aviron Investment Management, demonstrating strong confidence in Lumonus's technology and its potential to transform cancer care. Existing investors also continued their support, highlighting the company's consistent progress and promising future.
Lumonus specializes in developing AI solutions that streamline and optimize the complex processes involved in radiation oncology. Radiation oncology, a critical component of cancer treatment, involves carefully targeting cancerous tumors with high-energy radiation beams. This requires meticulous planning, precise execution, and continuous monitoring to ensure effective treatment while minimizing damage to healthy tissues.
Lumonus's AI platform assists clinicians at every stage of this process, from initial planning and simulation to treatment delivery and post-treatment analysis. By automating repetitive tasks, improving accuracy, and providing data-driven insights, Lumonus aims to reduce treatment times, enhance patient outcomes, and alleviate the burden on healthcare professionals.
The A$25 million investment will enable Lumonus to accelerate its research and development efforts, expand its team of experts, and broaden its reach to new markets around the world. This expansion will allow more cancer centers and patients to benefit from the company's innovative AI solutions, ultimately contributing to improved cancer treatment globally.
"This Series B funding is a significant milestone for Lumonus," said a company spokesperson. "It validates our vision of using AI to transform radiation oncology and improve the lives of cancer patients. We are excited to partner with Aviron Investment Management and our existing investors to bring our solutions to a wider audience and make a meaningful impact on the fight against cancer."
The investment in Lumonus underscores the growing importance of artificial intelligence in healthcare and its potential to revolutionize various aspects of medical practice. As the demand for personalized and efficient cancer treatment continues to rise, companies like Lumonus are poised to play a crucial role in shaping the future of oncology.
Category:
Politics